Skip to Main Content

Author Details

Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
2011
51
17
PMIDPaper TitleJournal TitlePublished Year
36880558The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.Br J Haematol2023
37643213Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma.Proc Natl Acad Sci U S A2023
36947202Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.Blood Adv2023
37067952Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.Blood Adv2023
34776244Concomitant diagnosis of chronic myeloid leukaemia and myeloma.Pathology2022
35459873Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.Leukemia2022
36436197Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2.Intern Med J2022
36274297Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?J Clin Neurosci2022
35879233Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.Intern Med J2022
33736721Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient.Infect Control Hosp Epidemiol2022
35152313Two cases of refractory IgG4-related disease successfully treated with tocilizumab.Ann Hematol2022
34972202Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.Blood Adv2022
34927329Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.Intern Med J2022
32981406Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.Leuk Lymphoma2021
34687398Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.Target Oncol2021
34625795Salvage radiotherapy is associated with durable response for a subset of patients with limited-stage refractory DLBCL.Blood Adv2021
34019788Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.Mol Cell2021
34151721Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.Leuk Lymphoma2021
34004147The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.Cell2021
33946635Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.J Pers Med2021
34047035COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.Intern Med J2021
33436370Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia.Cancer Discov2021
33259592Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.Blood2021
32609419Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.Intern Med J2021
32285612A consensus statement on the use of biosimilar medicines in hematology in Australia.Asia Pac J Clin Oncol2020
31827241A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.Leukemia2020
32864550Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy.Res Pract Thromb Haemost2020
32917631CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.Sci Adv2020
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
32843425Failure of tofacitinib to achieve an objective response in a <i>DDX3X-MLLT10</i> T-lymphoblastic leukemia with activating <i>JAK3</i> mutations.Cold Spring Harb Mol Case Stud2020
32415723Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.Intern Med J2020
32451706Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.Ann Hematol2020
30902969Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis.Nat Commun2019
31723826Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS.Hemasphere2019
31236941Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.Br J Haematol2019
28857117Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.Br J Haematol2018
31723793Efficacy of Zanubrutinib in the Treatment of Bing-Neel Syndrome.Hemasphere2018
28050677Cold agglutinin disease complicated by acrocyanosis and necrosis.Ann Hematol2017
28280273A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.Leukemia2017
28262675Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.Nat Commun2017
26801792Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.Ann Hematol2016
26627013The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.Cancer Res2016
27406984BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.Mol Cancer Ther2016
25578475CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.Leukemia2015
26681665Prevention and management of obinutuzumab-associated toxicities: Australian experience.Int J Nurs Pract2015
24811162Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.Curr Opin Hematol2014
23502429Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.Neuro Oncol2013
22544215Correct diagnosis of NK and T cell lymphomas.Pathology2012
23387003Disseminated histoplasmosis complicating HIV infection.Blood2012
23304710Passenger lymphocyte syndrome after lung transplant.Blood2012
  • 1 - 50 of 51

Recommended Authors

Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Shalin Kothari
Yale University
Career Start Year 2013
Number of shared co-authors 0
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 2
Sameer A Parikh
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 0
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 1
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Prapti Patel
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 2
Milos D Miljkovic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2009
Number of shared co-authors 0
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Geoffrey Shouse
City of Hope National Medical Center
Career Start Year 2007
Number of shared co-authors 2
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2006
Number of shared co-authors 2
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 0
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 3
Alexey V Danilov
City of Hope National Medical Center
Career Start Year 2005
Number of shared co-authors 3
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 2
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 2
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 0
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 2
Sze Fai Yip
Tuen Mun Hospital
Career Start Year 1999
Number of shared co-authors 0
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 10
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Career Start Year 1998
Number of shared co-authors 0
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Eric Tse
School of Clinical Medicine, University of Hong Kong
Career Start Year 1997
Number of shared co-authors 0
Francisco Vega
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 2
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 0
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 1
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 3
Kikkeri N Naresh
Fred Hutchinson Cancer Research Center
Career Start Year 1989
Number of shared co-authors 1
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 2
Stefania Pittaluga
National Cancer Institute, National Institutes of Health
Career Start Year 1979
Number of shared co-authors 0

Collaborators

Ricky W Johnstone
The University of Melbourne
Co-authored papers 15
Andrea Newbold
Peter MacCallum Cancer Centre
Co-authored papers 5
Maria A Doyle
Peter MacCallum Cancer Centre
Co-authored papers 2
Nathanael S Gray
Harvard Medical School
Co-authored papers 2
Jamal C Saeh
Oncology R&D
Co-authored papers 2
Anthony T Papenfuss
Co-authored papers 2
Stephen Fawell
Oncology R&D
Co-authored papers 2
Justin Cidado
Oncology R&D
Co-authored papers 2
Kristin K Brown
Co-authored papers 1
Michael Zinda
Repare Therapeutics Inc.
Co-authored papers 1
Gordon K Smyth
The University of Melbourne
Co-authored papers 1
William McCoull
Oncology R&D
Co-authored papers 1
Kaylene J Simpson
The University of Melbourne, Peter MacCallum Cancer Centre
Co-authored papers 1
Robert B Diebold
Oncology R&D
Co-authored papers 1
Andrew J Yee
Co-authored papers 1
Kate F Byth
Oncology R&D
Co-authored papers 1
Terry MacIntyre
Oncology R&D
Co-authored papers 1
Paula Lewis
Oncology R&D
Co-authored papers 1
Deborah Lawson
Oncology R&D
Co-authored papers 1
Nancy Su
Co-authored papers 1
Alwin G Schuller
Oncology R&D
Co-authored papers 1
James E Bradner
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Patricia Jaaks
Wellcome Sanger Institute
Co-authored papers 1
Kenneth D Bromberg
Co-authored papers 1
Jesper Q Svejstrup
Panum Institute, University of Copenhagen
Co-authored papers 1
Richard B Lock
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 1
Martin Wild
Oncology R&D
Co-authored papers 1
Michael Ohlmeyer
Atux Iskay LLC
Co-authored papers 1
Stephanos Ioannidis
H3 Biomedicine Inc.
Co-authored papers 1
Release 1.2